Association between COVID-19 infection and work exposure assessed by the Mat-O-Covid job exposure matrix in the CONSTANCES cohort

Marc Fadel, Fabien Gilbert, Clément Legeay, Vincent Dubée, Yolande Esquirol, Catherine Verdun-Esquer, Aurelien Dinh, Grace Sembajwe, Marcel Goldberg, Yves Roquelaure, Emmanuel Wiernik, Marie Zins, Alexis Descatha, Mat-O-Covid investigators

ABSTRACT
Objectives The COVID-19 pandemic has brought to light a new occupational health threat. We aimed to evaluate the association between COVID-19 infection and work exposure to SARS-CoV-2 assessed by a job-exposure matrix (JEM), in a large population cohort. We also estimated the population-attributable fraction among exposed subjects.

Methods We used the SAPRIS-SERO sample of the CONSTANCES cohort, limited to subjects actively working, and with a job code available and a questionnaire on extra work activities. The following outcomes were assessed: COVID-19 diagnosis made by a physician; a seropositivity to the ELISA-S test (‘serology strict’) and ELISA-S test intermediate with positive ELISA-NP or a positive neutralising antibodies SN (‘serology large’). Job exposure was assessed using Mat-O-Covid, an expert-based JEM with an index used as a continuous variable and a threshold at 13/1000.

Results The sample included 18999 subjects with 389 different jobs, 47.7% were men with a mean age of 46.2 years (±9.2 years). The Mat-O-Covid index taken as a continuous variable or with a threshold greater than 13/1000 was associated with all the outcomes in bivariable and multivariable logistic models. ORs were between 1.30 and 1.58, and proportion of COVID-19 attributable to work among exposed participants was between 20% and 40%.

Discussion Using the Mat-O-Covid JEM applied to a large population, we found a significant association between work exposure to SARS-CoV-2 and COVID-19 infection, though the estimation of attributable fraction among exposed people remained low to moderate. Further studies during other exposed periods and with other methods are necessary.

INTRODUCTION
Since its first detection in the latter part of 2019 until this year, the novel COVID-19 caused by the SARS-CoV-2 has spread worldwide and infected millions of people, quickly becoming a tremendous global challenge for healthcare workers and policy-makers. Front-line workers and now more broadly all workers are at risk of getting infected by SARS-CoV-2 at work, and occupational and public health units must deal with this new threat. 1\textsuperscript{-}3

Healthcare workers are clearly exposed to SARS-CoV-2 through their interaction with patients, but it is more difficult to assess occupational exposure to SARS-CoV-2 in non-healthcare settings. Many non-healthcare jobs are public-facing, resulting in varying levels of contact and close physical proximity to others, creating potential high-risk situations for infection. 4\textsuperscript{-}5 There are unresolved questions on exposure to SARS-CoV-2 attributable to work. A recent mortality study found that work confounding factors and mediating factors explained 20%–30% of the excess age-adjusted risks. 6 However, such evaluations should include, not only mortality, but also infection rates (prevalence and incidence) and need a robust evaluation of the role of work exposure.

Job-exposure matrices (JEMs) were developed to address the intricacies of work exposure. The JEM is a tool in occupational medicine used to estimate exposure to various workplace risk factors.
and has been shown to produce reliable and cost-effective exposure estimates that minimise bias due to individual variability from self-reports. Estimating occupational exposure to SARS-CoV-2 has become increasingly important, especially with the spread of viral variants worldwide and the advent of long-term COVID-19 symptoms (often referred to as postacute sequelae of COVID-19 or postacute COVID-19 syndrome) and the need to apply adapted preventive strategies. On this basis, Mat-O-Covid was created as a JEM to evaluate workplace exposures to SARS-CoV-2.2

In these analyses, we aimed to apply the COVID-19 JEM Mat-O-Covid to the large population-based cohort CONSTATCES that had available information on COVID-19 infection, to assess the association between work exposure and COVID-19 infection. Using these results, we also aimed to estimate the population-attributable fraction among subjects exposed (AFE) to SARS-CoV-2 at work.

### METHODS

#### Population

CONSTATCES is a French general population-based cohort.8 More than 200,000 participants, aged 18–69 years, were recruited between 2012 and 2020 in 26 health screening centres across France. The recruitment was limited to people affiliated with the French National Health Insurance Fund that comprises active or former salaried workers and their families and excludes agricultural and self-employed workers.8 At enrolment, self-administered questionnaires were sent to participants to collect data on lifestyle, life events, health and occupation. Variables of interest were collected from the baseline self-administered questionnaire and medical interviews. For this work, we used a subsample of CONSTATCES participants who were included in the SAPRIS-SERO COVID-19 study,9,10 limited to subjects who answered to be at work, and with an available job code.

In this sample, each participant filled out an online questionnaire between June and October 2020. In addition to age (categorised as <30 years, 30–40 years, 40–50 years, 50–60 years and ≥60 years) and sex, participants answered questions on a potential COVID-19 infection diagnosed by a physician, and on the following activities since the end of the lockdown, coded in three categories (none; yes one time; yes more than one time): family gatherings, leisure activities, regular shopping, visiting public places. Data on usage of protective measures outside of work (hand sanitiser and mask-wearing) were also collected in three categories: no; yes, after almost every outing; yes, systematically after every outing (including not or never go out).

Mat-O-Covid is an expert-based JEM which uses the profession and socioprofessional categories ‘Catégories Socioprofessionnelles PCS 2003’ (French Classification of Occupations) as job codes in the dataset. To create the exposure index, a group of four experts in different occupational fields independently coded the data on occupational exposure to SARS-CoV-2 using 0 (low/no exposure) to 1 (likely/very frequent exposure)11 and other experts similarly coded prevention methods (see box 1). This resulted in an index for each job associated with the probability of exposure to SARS-CoV-2 at work, called the ‘Mat-O-Covid index’.12 The index was used as a continuous variable with a threshold defined in a previous study (ie, 13/1000, above which exposure has definitively occurred).13

The study participants also received an invitation to perform a serology test by dried-blood spot (DBS) self-sampling. Participants living in mainland France, who completed the questionnaires and who agreed to the serology test, received a DBS kit to be returned to the centralised biobank after capillary blood collection (CEPH Biobank, Paris, France). Two waves of kits were sent out: the first was a random sample of participants in 3 of the 12 mainland French regions, the second was extended to include all regions of France and all consenting participants. The Elisa test (Euroimmun, Lübeck, Germany) was used to detect anti-SARS-CoV-2 antibodies (IgG) directed against the S1 domain of the spike protein of the virus (ELISA-S). In accordance with the manufacturer’s instructions, a test was considered to be ELISA-S-positive if the optical density ratio was ≥1.1, ELISA-S indeterminate between 0.8 and 1.1, and

| Box 1 | Mat-O-Covid |
|-------|-------------|
| 'Mat-O-Covid' is a job exposure matrix that was developed by a group of French experts to provide a global assessment of the probability of exposure and prevention of SARS-CoV2 only in the occupational field. This tool includes four elements that have been evaluated by experts, namely |
| **P1:** 0%–100%, with as an example the probability of close direct contact: 5 as unlikely/very infrequent, 30 possible/infrequent contact, 70 likely/very frequent contact. |
| **P2:** 0%–100%, with examples of probability of effective prevention: 5 as unlikely/very infrequent, 30 possible/infrequent prevention, 70 probable/very frequent prevention. |
| **P3:** 0%–100%, with an example of the probability of contact with an infected patient/virus: 5 as unlikely/very infrequent contact, 30 as possible/infrequent contact, 70 as likely/very frequent contact. |
| **P4:** 0%–100%, with examples of probability of effective prevention: 5 as unlikely/very infrequent, 30 possible/infrequent prevention, 70 probable/very frequent prevention. |

In a second step, it was necessary to calculate an overall probability of occupational contamination using four additional parameters:

1. **F1:** Overall probability factor of exposure to SARS-CoV2 among non-diseased working people (public/colleagues). This factor was estimated to be 100.
2. **F2:** Overall probability factor of exposure to SARS-CoV2 among sick patients encountered in the medicosocial sector. This factor was estimated at 10.
3. **F3:** Global factor of probability of exposure to SARS-CoV2 of the profession and social category, all sectors of activity combined, in comparison with the medicosocial sector. This factor is between 1 and 10.
4. **F4:** Global factor of virus circulation during the period considered. This factor is between 0 and 100.

For now, the F4 factor was evaluated at one for the moment. From the above, an average probability of occupational SARS-CoV2 contamination assessed by the P5 formula, adding the probabilities of subject and patient contact, weighted by preventive measures and additional factors.

\[
P5 = \frac{(P1 \times (1-P2)) \times F1 + (P3 \times (1-P4)) \times F2)}{F1 \times F2} \times F4 \times 1000
\]

The updated matrices are freely available in appendices of the papers (https://europepmc.org/article/PMC9091162/appendix1 in French https://europepmc.org/article/PMC9091162/bin/mmc1.xlsx, appendix 2 in English https://europepmc.org/articles/PMC9091162/bin/mmc2.xlsx).
ELISA-S-negative if <0.8. All samples with an ELISA-S test ≥0.7 were also tested with an ELISA test to detect IgG antibodies against the SARS-CoV-2 nucleocapsid protein (ELISA-NP) (Euroimmun, Lübeck, Germany), and with an in-house micro-neutralisation assay to detect neutralising anti-SARS-CoV-2 antibodies (SN), with a positive SN defined as a titre ≥40.24

Three outcomes were considered: (1) a reported infection diagnosed by a physician called ‘COVID-19 reported’, (2) seropositivity with the ELISA-S test only (ELISA-positive with an optical density ratio of ≥1.1), called ‘Serology strict’, (3) ‘Serology large’ or an indeterminate ELISA-S (between 0.8 and 1.1) with either a positive ELISA-NP or a positive SN, called ‘Serology large’.

Associations between the outcomes and the Mat-O-Covid index were calculated using univariable and multivariable logistic models adjusted for age, sex and extra work activities and use of protective measures outside of work. For extra work activities, the reference used was ‘yes, more than one time’ and for use of protective measures outside of work, ‘yes, systematically after every outing’. Differences of timing between questionnaires and serology were also considered in a two-category variable (3 months or more compared with less). All analyses were performed using Statistical Analysis System V9.4 (SAS Institute). Using the index variable in two categories from the bivariable and multivariable analyses, we calculated the AFE individuals which estimated the proportion of cases of COVID-19 attributable to work in the industries and occupations at high risk15: AFE = (OR – 1)/OR. Range was calculated using the 95% upper and lower limits of OR.

RESULTS

The sample with participants actively working included 18,999 subjects with 389 different jobs, with 47.7% of men and a mean age of 46.2 years (±9.2 years). Among them, 125 did not answer the COVID-19 question, 4437 lacked an Elisa test, and 4484 lacked an Elisa-SN and RN. Mean time between the questionnaire with occupation and the online questionnaire with COVID-19 information was of 2.8 months (±0.6) and mean time between the online questionnaire and serology was of 3.5 months (±1.0).

Before fall 2020, 613 subjects (3.3%) reported having COVID-19 diagnosed by a physician (‘COVID-19 reported’). In addition to being a woman and age between 30 and 40 years, Mat-O-Covid index was associated with ‘COVID-19 reported’, whereas subjects who reported no public places visits and use of hand sanitiser after almost every outing had a lower risk (table 1). Age (30–40 years), use of hand sanitiser after almost every outing, delayed questionnaire and Mat-O-Covid index remained significantly associated with ‘COVID-19 reported’ in multivariable analyses.

In the sample with ELISA serologies and ELISA-NP and SN testing (n=14,515), 1017 had a positive test (‘serology large’, 7.0%). In addition to being female and aged between 30 and 40 years, Mat-O-Covid index was associated with the ‘serology large’ outcome, whereas subjects older than 50 years and younger than 30 years, who reported no public places visited, use of hand sanitiser after almost every outing, and delayed questionnaire had a lower risk (table 2). Sex, age (less than 30 years or 50 years or more), use of hand sanitiser after almost every outing, delayed questionnaire and Mat-O-Covid index remained significantly associated with the ‘serology large’ outcome in multivariable analyses. In the sample with available ELISA testing (n=14,562), 911 had a positive test (‘serology strict’, 6.3%). A similar pattern of associations is observed in table 3.

Using the ORs obtained, we estimated proportion (and range) of COVID-19 cases attributable to work. We observed that the proportion of AFE people ranged between 20% and 40% (table 4).

DISCUSSION

Using the COVID-19 JEM Mat-O-Covid applied to a large population, we found a significant association between work exposure to SARS-CoV-2 and COVID-19 infection, though the estimation of attributable fraction among participants exposed at work exposure was low to moderate.

This is one of the first original studies to assess the contribution of work exposure to the risk of COVID-19 infection using three validated measures to evaluate the infection. The major strength of this study is the large sample size taken from a population-based cohort with different levels of diagnosis as outcomes. Indeed, using specific and broad definitions of serology allowed us to have a more accurate picture of the breadth and spread of contamination by SARS-CoV-2. Even though misclassification due to ELISA test is possible,7 it is unlikely that it is a source of differential bias as it should affect all exposure groups equally. Reported results also gave similar positivity outcomes, which makes us relatively confident in the association found.

The relationship between occupations and COVID-19 was studied widely among healthcare workers8 whereas other jobs were considered less often. Cluster analyses in Asia identified high risk populations, such as immigrants9 and occupations having an increased probability of being in contact with people.17 These results were similar to those of other studies, with protective service occupations, administrative support occupations, education occupations, community and social services occupations, and construction and extraction occupations having the highest risk.8

The other relevant factors associated with COVID-19 highlight the complexity of the process of contamination. The reported extra work activities were supposed to increase the probability of COVID-19 but were found only marginally associated with COVID-19, with few significant values (family contacts). However, protective measures were not found to be inversely associated with seroconversion, but they were for reported COVID-19. The ‘almost’ category of the variable ‘use of hand sanitiser’ seemed more protective than the ‘systematically’ category, which illustrates the complexity of the interpretation of such analyses. On the other hand, older age was inversely associated with seroconversion, but not with reported COVID-19. Younger age is probably associated with lower contamination, while older age is probably associated with lower contamination and/or lower antibody production, with a possible higher proportion of immunodeficiency in older subgroups.18–20 A recent study using the same data, found a non-linear relationship between seroconversion and age.10

Some limitations to our findings exist. The sample analysed was not representative of all working age groups because CONSTATNCES is not representative of the French population, and only online respondents of CONSTATNCES who agreed to participate and who sent a blood test were included. However, the size of the sample and the number of different jobs (389 of the 487 existing codes) should reduce the risk of job-level selection bias. Remote work was also possible even if it was not specifically investigated here. However, one parameter on the Mat-O-Covid JEM considered remote work as a potential prevention measure. As for the exposure assessment, in general, JEMs allow us to have a sense of the group-level exposure but tend to underestimate intra-job (individual-level) variations of exposure, and Mat-O-Covid has only recently been validated.12,21 However, potential measurement errors caused by the JEM assessed...
Table 1  Description of cases defined by reported COVID-19 by a physician and association with bivariant and multivariable analyses based on Mat-O-Covid index (continuous and categorised)

|                        | Total | No of cases | Proportion (%) | Crude ORs (95% CI) | Adjusted ORs*, Mat-O-Covid index continuous (95% CI) | Adjusted ORs*, Mat-O-Covid index categorised (95% CI) |
|------------------------|-------|-------------|----------------|---------------------|-----------------------------------------------------|-----------------------------------------------------|
| **Sex**                |       |             |                |                     |                                                     |                                                     |
| Men                    | 9000  | 262         | 2.91           | 1                   | 1                                                   | 1                                                   |
| Women                  | 9874  | 351         | 3.55           | 1.23 (1.04 to 1.45) | 1.16 (0.95 to 1.43)                                  | 1.17 (0.95 to 1.44)                                  |
| **Age**                |       |             |                |                     |                                                     |                                                     |
| <30 years              | 483   | 15          | 3.91           | 0.98 (0.58 to 1.68) | 1.15 (0.61 to 2.16)                                  | 1.13 (0.60 to 2.12)                                  |
| 30–40 years            | 4654  | 182         | 3.15           | 1.25 (1.02 to 1.53) | 1.32 (1.04 to 1.68)                                  | 1.32 (1.03 to 1.68)                                  |
| 40–50 years            | 6818  | 215         | 3.05           | 1                   |                                                     | 1                                                   |
| 50–60 years            | 5545  | 169         | 2.33           | 0.97 (0.79 to 1.18) | 1.03 (0.80 to 1.31)                                  | 1.03 (0.81 to 1.31)                                  |
| ≥60 years              | 1374  | 32          | 0.73           | 0.50 (1.07)         |                                                     | 0.64 (0.39 to 1.07)                                  |
| **Family meeting**     |       |             |                |                     |                                                     |                                                     |
| No                     | 662   | 14          | 2.11           | 0.64 (0.38 to 1.10) | 0.70 (0.36 to 1.37)                                  | 0.70 (0.36 to 1.37)                                  |
| Yes, one time          | 1253  | 47          | 3.75           | 1.16 (0.85 to 1.57) | 1.43 (1.00 to 2.06)                                  | 1.44 (1.00 to 2.06)                                  |
| Yes, more than one time| 16880 | 550         | 3.26           | 1                   |                                                     | 1                                                   |
| **Leisure activities** |       |             |                |                     |                                                     |                                                     |
| No                     | 4440  | 130         | 2.93           | 0.88 (0.72 to 1.07) | 0.88 (0.68 to 1.14)                                  | 0.88 (0.68 to 1.13)                                  |
| Yes, one time          | 1079  | 39          | 3.61           | 1.09 (0.78 to 1.52) | 1.32 (0.90 to 1.94)                                  | 1.33 (0.91 to 1.95)                                  |
| Yes, more than one time| 13272 | 441         | 3.32           | 1                   |                                                     | 1                                                   |
| **Regular shopping**   |       |             |                |                     |                                                     |                                                     |
| No                     | 369   | 6           | 1.63           | 0.49 (0.22 to 1.10) | 0.51 (0.19 to 1.37)                                  | 0.51 (0.19 to 1.37)                                  |
| Yes, one time          | 249   | 5           | 2.01           | 0.60 (0.25 to 1.47) | 0.71 (0.26 to 1.93)                                  | 0.71 (0.26 to 1.94)                                  |
| Yes, more than one time| 18165 | 596         | 3.28           | 1                   |                                                     | 1                                                   |
| **Public places visit**|       |             |                |                     |                                                     |                                                     |
| No                     | 2889  | 77          | 2.67           | 0.77 (0.60 to 0.98) | 0.75 (0.54 to 1.03)                                  | 0.75 (0.54 to 1.03)                                  |
| Yes, one time          | 2468  | 69          | 2.8            | 0.80 (0.62 to 1.04) | 0.74 (0.54 to 1.02)                                  | 0.74 (0.54 to 1.02)                                  |
| Yes, more than one time| 13446 | 464         | 3.45           | 1                   |                                                     | 1                                                   |
| **Use of hand sanitiset**|      |             |                |                     |                                                     |                                                     |
| No                     | 389   | 19          | 4.88           | 1.41 (0.88 to 2.26) | 1.04 (0.52 to 2.06)                                  | 1.04 (0.52 to 2.05)                                  |
| Yes, after almost every outing | 6208 | 164       | 2.64           | 0.75 (0.62 to 0.90) | 0.74 (0.59 to 0.93)                                  | 0.74 (0.59 to 0.92)                                  |
| Yes, systematically after each outing (or I never go out) | 12212 | 428 | 3.5 | 1 | 1 | 1 |
| **Wearing mask†**      |       |             |                |                     |                                                     |                                                     |
| No                     | 509   | 20          | 3.93           | 1.19 (0.74 to 1.91) | 1.33 (0.75 to 2.34)                                  | 1.33 (0.75 to 2.34)                                  |
| Yes, after almost every outing | 13599 | 434 | 3.19 | 0.96 (0.80 to 1.16) | 0.96 (0.76 to 1.21)                                  | 0.96 (0.76 to 1.21)                                  |
| Yes, systematically after each outing (or I never go out) | 4696  | 156         | 3.32           | 1                   |                                                     | 1                                                   |
| **Difference between questionnaires** |       |             |                |                     |                                                     |                                                     |
| Less than 3 month      | 13154 | 420         | 3.19           | 1                   | 1                                                   | 1                                                   |
| 3 months or more       | 5720  | 193         | 3.37           | 1.06 (0.89 to 1.26) | 1.04 (0.84 to 1.29)                                  | 1.04 (0.84 to 1.29)                                  |
| **Mat-O-Covid Index**  |       |             |                |                     |                                                     |                                                     |
| Continuous variable    | 18874 | 613         | 3.25           | 1.03 (1.01 to 1.04) | 1.02 (1.01 to 1.03)                                  |                                                     |
| ≥13 per thousand       | 11529 | 354         | 3.07           | 1                   |                                                     | 1                                                   |
| ≥13 per thousand       | 1549  | 82          | 5.29           | 1.76 (1.38 to 2.26) | 1.58 (1.22 to 2.04)                                  |                                                     |

Bold results: overall test, p<0.05.

*Adjusted for sex, age, family meeting, leisure activities, regular shopping, public places visit, use of hand sanitiset, wearing mask and time between questionnaires.
†Outside of work
### Table 2 Description of cases defined by ‘serology large’ and association with bivariable and multivariable analyses based on Mat-O-Covid index (continuous and categorised)

|                                | Total  | No of cases | Proportion (%) | Crude ORs (95% CI) | Adjusted ORs*, Mat-O-Covid index continuous (95% CI) | Adjusted ORs*, Mat-O-Covid index categorised (95% CI) |
|--------------------------------|--------|-------------|----------------|---------------------|--------------------------------------------------|-----------------------------------------------------|
| **Sex**                        |        |             |                |                     |                                                  |                                                     |
| Men                            | 6789   | 415         | 6.11           | 1                   | 1                                                 | 1                                                   |
| Women                          | 7726   | 602         | 7.79           | 1.30 (1.14 to 1.48) | 1.21 (1.03 to 1.42)                                 | 1.21 (1.03 to 1.42)                                  |
| **Age**                        |        |             |                |                     |                                                  |                                                     |
| <30 years                      | 336    | 14          | 4.17           | 0.47 (0.28 to 0.82) | 0.53 (0.29 to 0.99)                                 | 0.52 (0.28 to 0.97)                                  |
| 30–40 years                    | 3486   | 338         | 9.7            | 1.17 (1.01 to 1.36) | 1.15 (0.97 to 1.38)                                 | 1.15 (0.96 to 1.37)                                  |
| 40–50 years                    | 5315   | 446         | 8.39           | 1                   |                                                  |                                                     |
| 50–60 years                    | 4310   | 177         | 4.11           | 0.47 (0.39 to 0.56) | 0.44 (0.36 to 0.55)                                 | 0.44 (0.36 to 0.55)                                  |
| >=60 years                     | 1068   | 42          | 3.93           | 0.45 (0.32 to 0.62) | 0.43 (0.28 to 0.64)                                 | 0.43 (0.28 to 0.65)                                  |
| **Family meeting**             |        |             |                |                     |                                                  |                                                     |
| No                             | 497    | 24          | 4.83           | 0.66 (0.44 to 1.00) | 0.66 (0.39 to 1.11)                                 | 0.66 (0.39 to 1.12)                                  |
| Yes, one time                 | 950    | 65          | 6.84           | 0.96 (0.74 to 1.25) | 1.06 (0.77 to 1.46)                                 | 1.06 (0.77 to 1.47)                                  |
| Yes, more than one time        | 13023  | 926         | 7.11           | 1                   | 1                                                 | 1                                                   |
| **Leisure activities**         |        |             |                |                     |                                                  |                                                     |
| No                             | 3390   | 226         | 6.67           | 0.93 (0.80 to 1.09) | 1.02 (0.84 to 1.23)                                 | 1.02 (0.84 to 1.24)                                  |
| Yes, one time                 | 836    | 59          | 7.06           | 0.99 (0.75 to 1.30) | 1.15 (0.83 to 1.60)                                 | 1.15 (0.83 to 1.60)                                  |
| Yes, more than one time        | 10240  | 730         | 7.13           | 1                   | 1                                                 | 1                                                   |
| **Regular shopping**           |        |             |                |                     |                                                  |                                                     |
| No                             | 284    | 19          | 6.69           | 0.95 (0.59 to 1.51) | 0.94 (0.53 to 1.67)                                 | 0.94 (0.53 to 1.68)                                  |
| Yes, one time                 | 194    | 11          | 7.57           | 0.79 (0.43 to 1.46) | 0.89 (0.45 to 1.78)                                 | 0.90 (0.45 to 1.79)                                  |
| Yes, more than one time        | 13984  | 985         | 7.04           | 1                   | 1                                                 | 1                                                   |
| **Public places visit**        |        |             |                |                     |                                                  |                                                     |
| No                             | 2254   | 125         | 5.55           | 0.74 (0.61 to 0.90) | 0.84 (0.66 to 1.06)                                 | 0.84 (0.66 to 1.06)                                  |
| Yes, one time                 | 1947   | 135         | 6.93           | 0.94 (0.78 to 1.14) | 0.82 (0.65 to 1.04)                                 | 0.82 (0.65 to 1.04)                                  |
| Yes, more than one time        | 10273  | 755         | 7.35           | 1                   | 1                                                 | 1                                                   |
| **Use of hand sanitiser†**     |        |             |                |                     |                                                  |                                                     |
| No                             | 278    | 20          | 7.19           | 0.96 (0.61 to 1.53) | 0.84 (0.45 to 1.58)                                 | 0.84 (0.45 to 1.58)                                  |
| Yes, after almost every outing | 4696   | 287         | 6.11           | 0.81 (0.70 to 0.93) | 0.80 (0.67 to 0.95)                                 | 0.80 (0.67 to 0.95)                                  |
| Yes systematically after each outing (or I never go out) | 9507   | 708         | 7.45           | 1                   | 1                                                 | 1                                                   |
| **Wearing mask†**              |        |             |                |                     |                                                  |                                                     |
| No                             | 380    | 22          | 5.79           | 0.90 (0.58 to 1.42) | 0.91 (0.53 to 1.57)                                 | 0.91 (0.53 to 1.57)                                  |
| Yes, after almost every outing | 10607  | 771         | 7.27           | 1.15 (0.99 to 1.35) | 1.19 (0.98 to 1.44)                                 | 1.19 (0.99 to 1.45)                                  |
| Yes systematically after each outing (or I never go out) | 3490   | 222         | 6.36           | 1                   | 1                                                 | 1                                                   |
| **Difference between questionnaire and serology** |        |             |                |                     |                                                  |                                                     |
| Less than 3 months             | 2344   | 212         | 9.04           | 1                   | 1                                                 | 1                                                   |
| 3 months or more               | 12171  | 805         | 6.61           | 0.71 (0.61 to 0.83) | 0.69 (0.57 to 0.84)                                 | 0.69 (0.57 to 0.83)                                  |
| **Mat-O-Covid index**          |        |             |                |                     |                                                  |                                                     |
| Continuous variable            | 14515  | 1017        | 7.01           | 1.01 (1.00 to 1.02) | 1.01 (1.00 to 1.02)                                 | 1.01 (1.00 to 1.02)                                  |
| <13 per thousand               | 8950   | 618         | 6.91           | 1                   | 1                                                 | 1                                                   |
| ≥13 per thousand               | 1224   | 116         | 9.48           | 1.41 (1.15 to 1.74) | 1.33 (1.07 to 1.64)                                 |                                                      |

Bold results: overall test, p<0.05.

*Adjusted for sex, age, family meeting, leisure activities, regular shopping, public places visit, use of hand sanitiser, wearing mask and time between questionnaires.
†Outside of work.
Table 3  Description of cases defined by ‘serology strict’ and association with bivariable and multivariable analyses based on Mat-O-Covid index (continuous and categorised)

|                | Total | No of cases | Proportion (%) | Crude ORs (95% CI) | Adjusted ORs*, Mat-O-Covid index continuous (95% CI) | Adjusted ORs*, Mat-O-Covid index categorised (95% CI) |
|----------------|-------|-------------|----------------|--------------------|----------------------------------------------------|-----------------------------------------------------|
| **Sex**        |       |             |                |                    |                                                    |                                                     |
| Men            | 6804  | 377         | 5.54           | 1                  | 1                                                  | 1                                                   |
| Women          | 7758  | 534         | 6.88           | 1.26 (1.10 to 1.44) | 1.21 (1.02 to 1.43)                                 | 1.21 (1.02 to 1.43)                                 |
| **Age**        |       |             |                |                    |                                                    |                                                     |
| <30 years      | 338   | 12          | 3.55           | 0.45 (0.25 to 0.81) | 0.47 (0.24 to 0.93)                                 | 0.46 (0.23 to 0.91)                                 |
| 30–40 years    | 3499  | 304         | 8.69           | 1.17 (1.00 to 1.36) | 1.14 (0.95 to 1.37)                                 | 1.13 (0.94 to 1.36)                                 |
| 40–50 years    | 5332  | 402         | 7.54           | 1                  | 1                                                  | 1                                                   |
| 50–60 years    | 4323  | 154         | 3.56           | 0.45 (0.37 to 0.55) | 0.43 (0.34 to 0.54)                                 | 0.43 (0.34 to 0.54)                                 |
| ≥60 years      | 1070  | 39          | 3.64           | 0.46 (0.33 to 0.65) | 0.43 (0.28 to 0.66)                                 | 0.44 (0.28 to 0.67)                                 |
| **Family meeting** |     |             |                |                    |                                                    |                                                     |
| No             | 499   | 18          | 3.61           | 0.55 (0.34 to 0.88) | 0.48 (0.25 to 0.90)                                 | 0.48 (0.25 to 0.91)                                 |
| Yes, one time  | 955   | 57          | 5.97           | 0.93 (0.70 to 1.23) | 1.09 (0.78 to 1.52)                                 | 1.10 (0.79 to 1.53)                                 |
| Yes, more than one time | 13062 | 835        | 6.39           | 1                  | 1                                                  | 1                                                   |
| **Leisure activities** |       |             |                |                    |                                                    |                                                     |
| No             | 3401  | 195         | 5.73           | 0.89 (0.75 to 1.05) | 0.98 (0.80 to 1.20)                                 | 0.98 (0.80 to 1.21)                                 |
| Yes, one time  | 841   | 55          | 6.54           | 1.02 (0.77 to 1.36) | 1.22 (0.87 to 1.71)                                 | 1.22 (0.87 to 1.72)                                 |
| Yes, more than one time | 10271 | 659        | 6.42           | 1                  | 1                                                  | 1                                                   |
| **Regular shopping** |       |             |                |                    |                                                    |                                                     |
| No             | 285   | 16          | 5.61           | 0.88 (0.53 to 1.47) | 0.88 (0.47 to 1.64)                                 | 0.88 (0.47 to 1.64)                                 |
| Yes, one time  | 197   | 8           | 4.06           | 0.63 (0.31 to 1.28) | 0.75 (0.35 to 1.62)                                 | 0.75 (0.35 to 1.63)                                 |
| Yes, more than one time | 14027 | 885        | 6.31           | 1                  | 1                                                  | 1                                                   |
| **Public places visit** |       |             |                |                    |                                                    |                                                     |
| No             | 2260  | 113         | 5              | 0.74 (0.61 to 0.91) | 0.86 (0.67 to 1.11)                                 | 0.87 (0.68 to 1.11)                                 |
| Yes, one time  | 1950  | 114         | 5.85           | 0.88 (0.71 to 1.08) | 0.80 (0.62 to 1.03)                                 | 0.80 (0.62 to 1.03)                                 |
| Yes, more than one time | 10311 | 682        | 6.61           | 1                  | 1                                                  | 1                                                   |
| **Use of hand sanitiser†** |       |             |                |                    |                                                    |                                                     |
| No             | 280   | 18          | 6.43           | 0.96 (0.59 to 1.56) | 0.94 (0.50 to 1.75)                                 | 0.94 (0.50 to 1.76)                                 |
| Yes, after almost every outing | 4710  | 254        | 5.39           | 0.80 (0.69 to 0.93) | 0.79 (0.66 to 0.95)                                 | 0.79 (0.66 to 0.95)                                 |
| Yes, systematically after each outing (or I never go out) | 9537  | 637        | 6.68           | 1                  | 1                                                  | 1                                                   |
| **Wearing mask†** |       |             |                |                    |                                                    |                                                     |
| No             | 381   | 21          | 5.51           | 0.97 (0.61 to 1.54) | 0.94 (0.54 to 1.64)                                 | 0.94 (0.54 to 1.65)                                 |
| Yes, after almost every outing | 10636 | 690        | 6.49           | 1.15 (0.98 to 1.36) | 1.20 (0.98 to 1.47)                                 | 1.20 (0.98 to 1.47)                                 |
| Yes, systematically after each outing (or I never go out) | 3507  | 199        | 5.67           | 1                  | 1                                                  | 1                                                   |
| **Difference between questionnaire and serology** |       |             |                |                    |                                                    |                                                     |
| Less than 3 months | 2346  | 199        | 8.48           | 1                  | 1                                                  | 1                                                   |
| 3 months or more | 12216 | 712        | 5.83           | 0.67 (0.57 to 0.79) | 0.65 (0.54 to 0.79)                                 | 0.65 (0.54 to 0.79)                                 |
| **Mat-O-Covid Index** |       |             |                |                    |                                                    |                                                     |
| Continuous variable | 14562 | 911        | 6.26           | 1.01 (1.00 to 1.02) | 1.01 (1.00 to 1.02)                                 | 1.01 (1.00 to 1.02)                                 |
| <13 per thousand | 8984  | 560         | 6.23           | 1                  | 1                                                  | 1                                                   |
| ≥13 per thousand | 1227  | 103         | 8.39           | 1.38 (1.11 to 1.72) | 1.30 (1.03 to 1.63)                                 |                                                     |

Bold results: overall test, p <0.05.

*Adjusted for sex, age, family meeting, leisure activities, regular shopping, public places visit, use of hand sanitiser, wearing mask and time between questionnaires.
†Outside of work.
exposure should lead to an attenuation bias and the population attributable fraction could be underestimated. Furthermore, it was necessary to check if the subjects did not change their jobs since 2020. Results with work exposure that were moderately but significantly associated with COVID-19 contamination showed that such exposure evaluations seemed to be accurate. Confounding factors that modify exposure were possible, and we could not address some of these exposures. The authors thank Pr. F. Carrat, Sobonne Université, Inserm, Institut Pierre Louis d’Épidémiologie et de Santé Publique, Département de Santé Publique, Hôpital Saint-Antoine, APHP, Paris, France, for his contribution to the SAPRIS project.

**Collaborators**

Mat-O-Covid investigators List/group: Alexis Descatha (CHU/Univ Angers), Marc Fadel (Univ Angers/ AP-HP), Sabrina Pifret (CHU Angers), Fabien Gilbert (Univ Angers), Rémi Valter (AP-HP, Paris), Catherine Verdon-Esquer (CHU Bordeaux), Yolande Esquirol (CHU/Univ Toulouse III), Clément Legeay (CHU Angers), Audrey Petit (CHU Angers), Aurélien Dinh (AP-HP, Paris, Saclay Univ), Pascal Andujar (Univ Paris Est Créteil, Créteil Hospital), Jean-Pierre Leclerc (INRS, Nancy), Corinne Letheux (Pessac, Paris), Pascal Duprat (DIRECCTE Région, Paris), Brigitte Clodoré (Ville de Paris), Sandrine Cartigné (SISBIT, La Réunion), Céline Dagenet (CMIE, Paris), William Dab (CNAM, Paris), Bénédicte Clin-Godard (CHU Caen), Jean-François Gehan (CHU Rouen), Vincent Dubé (Univ Angers/CHU Angers), Philippe Havette (La Poste, Paris).

**Contributors**

Conceptualization and guarantor, AD. Methodology, AD, GS and MF and Mat-O-Covid investigators. Data management, FG; Validation, all authors. Formal analyses, AD. Interpretation of analyses, MF, FG, CL, YD, YE, CV-E, AD, GS, MG, YR, AL, EW, MZ and Mat-O-Covid investigators. Writing—original draft preparation, MF, AD. Writing—review and editing FG, CL, YD, YE, CV-E, AD, GS, MG, YR, AL, EW, MZ and Mat-O-Covid investigators. All authors have read and agreed to the published version of the manuscript.

**Funding**

Mat-O-Covid is funded by REACTing Inserm (Mat-O-Covid project), ANRS (Emerging Infectious Diseases since 2021); Regional Public Fund (TEC-TOP project); Pays de la Loire Region, Angers Loire Métropole, Univ Angers, CHU Angers. The CONSTATES Cohort Study was supported and funded by the French National Health Insurance Fund (‘Caisse nationale d’assurance maladie’, CNAM). The CONSTATES Cohort Study is an ‘Infrastructure nationale en Biologie et Santé’ and benefits from a grant from the French National Agency for Research (ANR-11-INBS-0002). CONSTATES is also partly funded by Merck Sharp & Dohme (MSD), Astrazeneca, Lundbeck and L’Oréal through Inserm-Transfert. SAPRIS-Sérologie (SERD) study was supported by grants ANR-10-COH-06 and ANR-20-COVI-001 from the Agence Nationale de la Recherche; grant 20DMIA014-0 from Santé Publique France; grant 20RR052-00 from the Fondation pour la Recherche Médicale; and grant C20-26 from INSERM. None of these funding sources had any role in the design of the study, collection and analysis of data or decision to publish.

**Competing interests**

Authors are paid by their institution, AD is also paid as editor of the Archives des Maladies professionnelles et de l’Environnement (Elsevier).

**Patient consent for publication**

Not applicable.

**Ethics approval**

This study involves human participants and was approved by The Mat-O-Covid study was approved by the Angers University Hospital ethic committee (approval #2021-009). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data availability statement**

Data may be obtained from a third party and are not publicly available. The data of the CONSTATES cohort are protected by our national regulatory agency (‘Commission nationale de l’informatique et des libertés’, no 910486). However, the CONSTATES cohort is ‘an open epidemiological laboratory’ and access to study protocols and data is available on justified request.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the license is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

**ORCID iDs**

Marc Fadel  http://orcid.org/0000-0002-1554-0021
Yolande Esquirol  http://orcid.org/0000-0002-2235-0320
Grace Sembajwe  http://orcid.org/0000-0002-7163-4743
Yves Roquelaure  http://orcid.org/0000-0001-6918-0909
Annette Leclerc  http://orcid.org/0000-0003-0868-1552
Alexis Descatha  http://orcid.org/0000-0001-6028-3186

**REFERENCES**

1. Heymann DL, Shindo N, WHO Scientific and Technical Advisory Group for Infectious Hazards. COVID-19: what is next for public health? Lancet 2020;395:542–5.
2. Sim MR. The COVID-19 pandemic: major risks to healthcare and other workers on the front line. Occup Environ Med 2020;77:281–2.
3. Burford A, Porru F, Ruggles R. The COVID-19 pandemic: one year later - an occupational perspective. Scand J Work Environ Health 2021;47:245–7.
et al. COVID-19 and healthcare workers: a systematic review and meta-analysis. Int J Infect Dis 2021;104:335–46.

5 Paris C, Tadé E, Heslan C, et al. Risk factors for SARS-CoV-2 infection among health care workers. Am J Infect Control 2022;50:375–82.

6 Nafiliyan V, Pavelek P, Ayoubkhani D, et al. Occupation and COVID-19 mortality in England: a national linked data study of 14.3 million adults. Occup Environ Med 2022;79:433–41.

7 Fadel M, Salomon J, Descatha A. COVID-19 job exposure matrix from the Mat-O-Covid design to its execution. J Occup Environ Med 2021;63:e168.

8 Goldberg D, Carton M, Descatha A, et al. CONSTANCES: a general prospective population-based cohort for occupational and environmental epidemiology: cohort profile. Occup Environ Med 2017;74:66–71.

9 Carrat F, Figoni J, Henry J. Evidence of early circulation of SARS-CoV-2 in France: findings from the population-based “CONSTANCES” cohort. Eur J Epidemiol 2021;1–4.

10 Carrat F, Lapidus N, Ninove L, et al. Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France. Infection 2022;50:257–62.

11 Descatha A, Fadel M, Pitot S. SARS-CoV-2 (COVID-19) Job Exposure Matrix: “Mat-O-Covid” Creation (COVID-Mate in French), accuracy study, and perspectives. Arch Mal Prof Environ 2021 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321772/

12 Descatha A, Pitot S, Badreau M. Mat-O-Covid : comment l’utiliser ? Mat-O-Covid: How to use it. Arch Mal Prof Environ 2022;83:215–9.

13 Descatha A, Sembajwe G, Gilbert F, et al. Mat-O-Covid: validation of a SARS-CoV-2 job exposure matrix (JEM) using data from a national compensation system for occupational COVID-19. Int J Environ Res Public Health 2022;19:5733.

14 Gallian P, Pastorino B, Morel P, et al. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Res 2020;181:104880.

15 Armitage P, Berry G, Matthews NJS. Statistical methods in medical research. 4th ed. Malden, MA: Wiley-Blackwell, 2001.

16 Tejamaya M, Phanprisi W, Kim J, et al. Characteristics of COVID-19 infection clusters occurring among workers in several Asia-Pacific countries. Ind Health 2022. doi:10.2486/indhealth.2021-0227. [Epub ahead of print: 12 Jan 2022].

17 Lan F-Y, Wei C-F, Hsu Y-T, et al. Work-Related COVID-19 transmission in six Asian countries/areas: a follow-up study. PLoS One 2020;15:e0233588.

18 Wise T, Zbozinek TD, Michelleini G, et al. Changes in risk perception and self-reported protective behaviour during the first week of the COVID-19 pandemic in the United States. R Soc Open Sci 2020;7:200742.

19 Pasion R, Paiva TD, Fernandes C, et al. The age effect on protective behaviors during the COVID-19 outbreak: sociodemographic, perceptions and psychological accounts. Front Psychol 2020;11:561785.

20 Lipstch M, Krammer F, Regev-Yochay G, et al. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol 2022;22:57–65.

21 Descatha A, Fadel M, Sembajwe G, et al. Job-Exposure matrix: a useful tool for incorporating workplace exposure data into population health research and practice. Front Epidemiol 2022;2 https://www.frontiersin.org/article/10.3389/fepid.2022.857316

22 Billingsley S, Branden M, Aradhy S, et al. COVID-19 mortality across occupations and secondary risks for elderly individuals in the household: a population register-based study, Scand J Work Environ Health 2022;48:52–60.